Kedrion Highlights Earlier Diagnosis of Acquired Immune Deficits
An expert call highlighted by Kedrion links earlier recognition of acquired immune deficits to the growing use of immunosuppressive and biological therapies.

Key facts
- Development: Experts called for earlier diagnosis of secondary immunodeficiencies.
- Setting: ESID 2026 in Maastricht, the Netherlands.
- Date: October 14, 2026.
- Clinical driver: Growing use of immunosuppressive and biological therapies.
Kedrion highlighted an expert call at ESID 2026 in Maastricht for earlier diagnosis of secondary immunodeficiencies as growing use of immunosuppressive and biological therapies increases their clinical relevance.
Kedrion highlighted a call from experts at ESID 2026 in Maastricht, the Netherlands, for earlier diagnosis of secondary immunodeficiencies, drawing attention to a healthcare challenge that can be overlooked as treatment becomes more complex.
The October 14 message connects the growing clinical relevance of these conditions to increasing use of immunosuppressive and biological therapies. The practical issue is not simply whether a treatment works against its intended disease. It is also whether clinicians recognize changes in immune function that may require a separate assessment.
For patients, healthcare providers and the life-science sector, the distinction matters. Better recognition could change the path through care, but a call for earlier diagnosis is not itself evidence that a particular screening program, medicine or treatment strategy improves outcomes.
Why secondary immune deficits need separate attention
Secondary immunodeficiency means impaired immune function that develops in association with another condition or an external influence, rather than an inherited immune disorder. In the context highlighted by Kedrion, the concern is the expanding use of therapies that alter or suppress immune activity.
Immunosuppressive therapies reduce immune activity. Biological therapies are a broad class of treatments made using biological systems; some act on components of the immune system. These categories should not be treated as interchangeable, and their effects depend on the particular therapy and patient.
The expert appeal, described by PR Newswire Biotech, frames secondary immunodeficiencies as an important and often insufficiently recognized healthcare challenge. It does not establish that every person receiving an immunosuppressive or biological treatment develops an immune deficit.
That distinction is essential to interpreting the message. A reason to assess risk is not a diagnosis, and a diagnosis does not automatically determine treatment. Earlier recognition should support more informed clinical decisions, not indiscriminate labeling of patients.
Earlier diagnosis is a care-pathway question
The central operational question is where recognition fits into a patient's existing care. Someone receiving treatment for an underlying illness may already have appointments, tests and medication reviews. Assessing immune function introduces another clinical question: whether findings reflect the original illness, treatment effects or a separate problem requiring attention.
A useful care pathway would clarify who evaluates that question, when specialist input is appropriate and how the findings reach the clinicians managing the underlying disease. Without clear responsibility, an additional assessment can become disconnected from the decisions it is meant to inform.
Earlier diagnosis also needs a defined purpose. Detecting a possible problem sooner is most useful when clinicians can explain what would change as a result. That might involve further evaluation, a different monitoring approach or a discussion of treatment choices, depending on the individual circumstances.
The Maastricht message supplies the direction of the appeal, not a detailed protocol. It does not provide a testing schedule, diagnostic threshold or quantified reduction in complications. Those details would be necessary before turning the appeal into a uniform practice standard.
Patients need recognition without unnecessary alarm
The Maastricht message supplies the direction of the appeal, not a detailed protocol.
For patients, the message is about recognition rather than an instruction to stop treatment. A medicine that affects immune activity may be important to controlling the condition for which it was prescribed. Decisions about continuing, adjusting or replacing it require an assessment of benefits and risks.
The language used in patient communication therefore matters. Explaining that a therapy can affect immune function is different from telling someone that they have an immunodeficiency. Clinicians need to distinguish a potential risk, a finding that requires investigation and an established diagnosis.
Patients also need to understand which care team is responsible for follow-up. When treatment and immune assessment involve different clinicians, uncertainty about responsibility can complicate the next step. Clear explanations and communication between teams are practical priorities, even before a new treatment is considered.
No patient-level findings or measured outcomes are supplied with the appeal. It would therefore be premature to claim that earlier diagnosis, as discussed at ESID 2026, has already reduced infections, hospital use or treatment interruptions. Those remain outcomes against which a proposed approach could be evaluated.
The industry implication is broader than a product
For the life-science sector, the issue illustrates how a treatment's clinical setting extends beyond its immediate target. As therapies become part of care, providers must consider how to recognize and manage effects elsewhere in the patient's health.
That creates a potential need for clearer diagnostic pathways, clinical education and coordination between specialties. It does not establish a commercial opportunity of a particular size. The supplied information contains no sales forecast, reimbursement decision or estimate of the population that would qualify for treatment.
Kedrion's involvement in highlighting the appeal should likewise not be read as a product-specific finding. The stated development is an expert call for earlier diagnosis. There is no supplied clinical-trial result, regulatory approval or evidence supporting a particular medicine for a defined group of patients.
The business significance will depend on whether awareness translates into identifiable changes in practice. More discussion alone does not show that testing has expanded, access has improved or treatment demand has increased.
Evidence and implementation are the next tests
The next useful developments would make the appeal more actionable: a clear description of patients who warrant assessment, agreement on diagnostic criteria and evidence showing how recognition changes subsequent care. These are questions to watch, not measures announced in the supplied material.
Implementation would also require attention to capacity. An assessment pathway has limited value if patients cannot obtain the necessary evaluation or if results do not reach the team making treatment decisions. The relevant test is a connected process, rather than the addition of an isolated test.
The immediate takeaway from Maastricht is narrow but consequential. Increasing use of immunosuppressive and biological therapies makes acquired immune deficits a more relevant clinical concern. The challenge now is to translate the call for earlier recognition into clear, evidence-based decisions without overstating what the appeal has demonstrated.
Frequently asked questions
What did Kedrion highlight at ESID 2026?
Kedrion highlighted an expert call for earlier diagnosis of secondary immunodeficiencies at ESID 2026 in Maastricht, the Netherlands. The message described these conditions as an important, often insufficiently recognized healthcare challenge whose clinical relevance has increased alongside growing use of immunosuppressive and biological therapies.
What is secondary immunodeficiency?
Secondary immunodeficiency is impaired immune function that develops in association with another condition or an external influence, rather than an inherited immune disorder. The discussion highlighted by Kedrion concerns its increasing relevance as immunosuppressive and biological therapies become more widely used. An individual diagnosis requires clinical evaluation.
Do biological therapies always cause immunodeficiency?
No. Biological therapies are a broad category, and their effects depend on the specific treatment and the patient. The expert call highlighted by Kedrion links growing use of these therapies to greater clinical relevance of secondary immunodeficiencies; it does not say that every patient receiving a biological therapy develops one.
Does the call establish that earlier diagnosis improves outcomes?
The supplied information does not include measured patient outcomes or a comparison demonstrating benefits from earlier diagnosis. It supports an expert appeal for better recognition. Establishing an outcome benefit would require evidence connecting earlier identification to meaningful changes in care, rather than assuming that detection alone produces improvement.
Should patients stop immunosuppressive treatment because of this news?
The expert appeal is not an instruction to stop treatment. Immunosuppressive therapy may be important for controlling an underlying illness, and treatment decisions require an individualized assessment of benefits and risks. Patients with concerns about immune function should discuss assessment and follow-up with the clinician responsible for their care.
What would make the expert appeal more actionable?
Clear patient-selection criteria, diagnostic standards and defined responsibilities for follow-up would help turn an awareness message into a practical care pathway. Evidence showing how diagnosis changes management would also matter. The supplied information does not announce a testing schedule, treatment protocol or quantified improvement in patient outcomes.
Sources
- Kedrion: en ESID 2026, los expertos piden un diagnóstico más temprano de las inmunodeficiencias secundarias — PR Newswire Biotech
Photo: Mitrey · Pixabay Content License — source
Filed under World News


